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ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant adverse ef-
fect of the otherwise impressive response of BRAFV600E-mutated melanomas to RAF inhibitors. In this issue
of Cancer Cell, Holderfield and colleagues show that RAF autoinhibition underpins this paradox, further
complicating therapeutic strategies centered around RAF.The addiction of cancers to driver onco-
proteins has been exploited in the design
of novel therapies for cancer treatment;
there have been numerous success stor-
ies in translating this approach to the
clinic. BRAFV600E is a founder, oncogenic
driver mutation detected in 50% of hu-
man malignant melanomas. Tumors
bearing this mutation are remarkably sen-
sitive to ATP competitive RAF kinase in-
hibitors, notably vemurafenib (PLX4032)
and dabrafenib (GSK2118436) (Flaherty
et al., 2010). Resistance to many targeted
therapies is associated with longer-term
treatment, and, although the initial
response to the drug is impressive,
certainly in the case of vemurafenib, resis-
tant tumors re-emerge after 2–18 months
of treatment.
Apart from acquired drug resistance,
the use of RAF inhibitors, unlike other tar-
geted agents, introduces an additional
confounding issue that arises due to
unique complexities of RAF regulation:
ERK pathway activation in cells bearing
oncogenic or normally activated RAS.
This phenomenon of ‘‘paradoxical activa-
tion’’ was initially reported in cancer cell
lines bearing RAS mutations and was
supported by data utilizing a mouse
model expressing kinase inactive BRAF
(Heidorn et al., 2010). Subsequently, the
phenomenon has been shown to accountfor the emergence of squamous cell car-
cinomas (SCCs), many of which bear
RAS mutations, in 15%–30% of vemura-
fenib-treated human melanoma patients
(Su et al., 2012). SCCs are not consid-
ered to be a threat to patients as they
are well differentiated, nonmetastatic,
and relatively easy to remove because
they arise on the skin. However, there is
always the concern (although not yet
proven) that drug treatment may accel-
erate progression of RAS-driven internal
lesions that are more difficult to detect.
Consequently, there has been a drive to
understand the mechanisms underpin-
ning ERK reactivation and to design
novel therapies that may circumvent this
problem. Paradoxical activation mecha-
nisms have also been proposed to
explain drug resistance acquired in
BRAFV600E mutant melanomas in situa-
tions where a spliced truncated variant
of BRAFV600E lacking a RAS-binding
domain is expressed (Poulikakos et al.,
2011).
Inhibitor-induced ERK pathway activa-
tion in cells expressing BRAFWT requires
RAF dimerization and transactivation pro-
moted by active RAS (Hatzivassiliou et al.,
2010; Heidorn et al., 2010; Poulikakos
et al., 2010). Initial reports proposed that
inhibitor-bound BRAF acts as a scaffold
to enhance CRAF activity at the plasmamembrane following RAS-induced
BRAF-CRAF heterodimer formation.
However, in a separate study, Poulikakos
et al. (2010) demonstrated RAF homo-
dimer and heterodimer formation in
response to inhibitor and proposed a
model whereby inhibitor binding to one
protomer of the RAF homo- or hetero-
dimer leads to its inhibition but causes
transactivation of the other inhibitor-free
protomer. Furthermore, transactivation
was not diminished in BRAF null cells,
highlighting a dominant role of CRAF ho-
modimers. In BRAFV600E tumors, RAS is
inactive and BRAF remains a monomer,
transactivation of RAFWT is not possible,
and inhibition of BRAFV600E becomes
dominant. The importance of dimerization
was supported by analysis of dimerization
mutants (CRAFR401A and BRAFR509H) that
prevented inhibitor-induced transactiva-
tion (Hatzivassiliou et al., 2010). Overall,
these studies led to the hypothesis that
development of non-ATP competitive in-
hibitors that prevent RAF dimerization
would prevent the adverse transactivation
effects.
A novel mechanism involving RAF
autoregulation has now been identified
by Holderfield et al. (2013), in this issue
of Cancer Cell, which changes the thera-
peutic approach significantly. This group
developed nine compounds with varyingl 23, May 13, 2013 ª2013 Elsevier Inc. 561
Figure 1. Novel Role of RAFAutophosphorylation and Autoinhibition
in Paradoxical ERK Activation
(A) At physiological ATP concentrations, RAF is autoinhibited by trans-P loop
phosphorylation of one RAF protomer by the other protomer within a dimer
(residues S359 in CRAF and S465/467 in BRAF). These events render RAF
inactive and downstream ERK signaling low.
(B) Low to intermediate levels of compound prevent transphosphorylation of
one RAF protomer. The nonphosphorylated protomer becomes active, result-
ing in high ERK signaling.
(C) At high compound concentrations, RAF protomers are inhibited and trans-
phosphorylation is prevented. Although RAF protomers are no longer autoinhi-
bited, compound levels are sufficiently high to displace ATP from the catalytic
clefts and inactivate all RAF protomers, blocking downstream ERK activation.
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Previewspotencies against RAF, all
of which inhibited the ERK
pathway in BRAFV600E-bear-
ing human melanoma cells
but induced ERK activation
in KRAS mutant (BRAFWT)
cells. Further analysis using
purified proteins showed
the activities of BRAFWT and
CRAFWT kinase domains
could be blocked by the
compounds but only at sub-
physiological concentrations
of ATP (1 mM). Furthermore,
ATP concentration negatively
correlated with RAF activity
and, at ATP concentrations
resembling cellular condi-
tions (1–5 mM), BRAFWT and
CRAFWT activities greatly
diminished, while that of
BRAFV600E increased. The
authors suggest ATP-depen-
dent RAF inhibition and the
stable nature of the inhibition
supported a covalent modifi-
cation such as phosphoryla-
tion. The work demonstrated
the need for RAF catalytic
activity for ATP-dependent
inhibition, and the authors
postulated that inhibitor acti-
vation of RAFWT was through
the prevention of RAF autoin-
hibition (Figure 1).
To explore the mecha-
nisms of autoinhibition, Hold-
erfield et al. (2013) per-
formed mass spectrometryof BRAFWT and CRAFWT in the presence
of 1 mM ATP. Serine 359 in CRAF and
serines 465 and 467 in BRAF, within the
glycine-rich phosphate-binding (P) loops,
were identified as being important for
inhibitory phosphorylation. In HEK293
cells, CRAFS359A was unable to increase
phospho-ERK levels in response to RAF
inhibitors; BRAF mutants were not tested
in this system as overexpression of
BRAFWT was unable to induce com-
pound-dependent ERK phosphorylation.
As expected, BRAFV600E was found not
to be regulated by autoinhibition; conse-
quently, the authors investigated several
other frequently occurring non-V600E
mutations in cancer, namely glycines
464, 466, and 469 within the P loop, and
found G464 mutations also disrupted
BRAF autoinhibition and compound-562 Cancer Cell 23, May 13, 2013 ª2013 Elsinduced activation in vitro. The authors
suggest that P loop autophosphorylation
may stabilize the inactive ‘‘DFG-out’’
conformation of RAF, leading to autoinhi-
bition, and propose that P loop mutations
of BRAF detected in human cancers may
render the enzyme unresponsive to P
loop autophosphorylation.
To examine the relationship between
RAF autoinhibition and dimerization, cell
lines with coincident KRASG12/13D and
BRAFG464E/V mutations were analyzed. In
cells with P loop mutations, the pre-
sence of activated RAS could not drive
compound-dependent ERK pathway
activation, even though BRAF-CRAF
heterodimerization was demonstrated.
Furthermore, mutation of the inhibitory
serine (S359A) rescued the kinase
activity of the dimerization incompetentevier Inc.CRAFR401A mutant, suggest-
ing that monomeric CRAF
can become active through
the relief of autoinhibition by
blocking P loop phosphoryla-
tion. These data led the
authors to speculate that P
loop autophosphorylation is
the dominant event over RAF
dimerization in compound-
induced RAF activation.
RAF regulation is an in-
credibly complex process




dimerization, and binding of
adaptor proteins (Wellbrock
et al., 2004). Autoinhibition of
the RAF catalytic domain by
the N-terminal domain has
been known for many years,
and this inhibition is relieved
by binding to activated RAS.
Sites of phosphorylation in
RAF, particularly CRAF, are
numerous, but studies of the
known regulatory phosphory-
lation sites have so far only
identified S621 in CRAF as
an autoregulated event (Noble
et al., 2008). The RAF P loop
phosphorylations identified
by Holderfield et al. (2013)
have not been previously
documented, despite exten-
sive searches for regulatory
RAF phosphorylation events,possibly because ATP concentrations
utilized in previous studies were too low.
The new data are important as they shed
light on themechanisms of RAF autoregu-
lation (Figure 1), provide an explanation
for P loop BRAF mutations in human
cancers, and question strategies for over-
coming paradoxical activation of the ERK
pathway in drug-treated situations.
An ideal RAF inhibitor would be one that
preserves potency but does not hyperac-
tivate RAF. These new data question
whether this can ever be a reality, as a
more potent drug will be more potent at
relieving RAF autoinhibition (Figure 1). A
dimer interface peptide that inhibits RAF
dimerization has been shown to suppress
ERK pathway activation in cells express-
ing lower activity RAF mutants (Freeman
et al., 2013), but the recent data suggest
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Previewsthis may not be the answer. Administering
higher doses of drug to patients is not an
option because of off-target effects and
toxicities. Due to its unique complexities,
perhaps it is time to look beyond RAF?
MEK inhibitors are showing promise in
the clinic while we all eagerly await clinical
data on inhibitors targeting ERK.REFERENCES
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In this issue of Cancer Cell, Be´guelin and colleagues highlight EZH2 as an essential regulator for B cell
activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible
process is specifically targetable and hence presents high translational value for lymphoma therapy.The enhancer of zeste homolog 2 (EZH2)
is a SET domain containing methyl-
transferase catalyzing the methylation
of histone H3, forming the transcrip-
tional repressive epigenetic mark
H3K27me3. EZH2 is a subunit of a
multi-enzyme complex known as poly-
comb repressive complex 2 and is
involved in chromatin compaction and
gene repression. EZH2 is expressed in
undifferentiated stem and progenitor
cell types but predominantly silenced in
somatic cells. Despite its repressive
function through H3K27 tri-methylation,
it frequently co-localizes with the acti-
vating histone modification H3K4me3.
These bivalently marked genes present
minimal expression level in undiffer-
entiated cells, but upon differentiation
initiation, lose H3K27me3 and are tran-
scriptionally activated.Lymphogenesis represents a special
case wherein EZH2 is repressed in resting
naive B cells, but is highly upregulated in
primary lymphoid follicles during B cell
activation and germinal center (GC) for-
mation (Velichutina et al., 2010). Herein,
EZH2 defines a GC-specific repression
profile including silencing of cell cycle
checkpoints and differentiation factors.
This epigenetic setting allows rapid B
cell proliferation, an important step during
the maturation process in germinal cen-
ters. Consistently, EZH2 silencing results
in cell cycle arrest at G1/s transition
(Velichutina et al., 2010). In line with its
proliferation promoting function, EZH2
was shown to be highly expressed in
GC-derived lymphomas, such as diffuse
large B cell lymphomas (DLBCLs) (van
Kemenade et al., 2001). Moreover, muta-
tions in the SET domain, favoring theformation of trimethylated H3K27, have
recently been reported as frequent events
in DLBCL (Morin et al., 2011). EZH2
mutant tumor cells are almost exclusively
detected in the GC-derived subtype,
affecting about 20% of GCB-DLBCL
patients and suggesting a subtype-spe-
cific function of the alteration. Clinically,
mutant EZH2 can be specifically targeted
using small molecule inhibitors, such
as GSK126 (McCabe et al., 2012).
Following drug application, EZH2 mutant
lymphoma cells revealed reduced levels
of H3K27me3 and, most importantly, pre-
sented a highly impaired proliferative
potential in vitro and in mouse DLBCL
xenograft models.
Although there is clear evidence for
the contribution of EZH2 to B cell matura-
tion and neoplastic transformation in
GCB-DLBCLs, the underlying molecularl 23, May 13, 2013 ª2013 Elsevier Inc. 563
